LONDONOne of Roche Holding AGs most promising new drugsfor women with an aggressive form of breast cancerhas been rejected by the panel that advises the UK health service on the grounds that it is too expensive The decision by the National Institute for Health and Care Excellence known as NICE reflects growing pressure on drug companies from health authorities in Europe and US insurers over pricing Irelands
  